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ABSTRACT: With the recent introduction of Poly(ADP-
ribose) polymerase inhibitors, a promising novel therapy
has become available for ovarian carcinoma (OC) patients
with inactivatingBRCA1 orBRCA2mutations in their tu-
mor. To select patients who may benefit from these treat-
ments, assessment of the mutation status of BRCA1 and
BRCA2 in the tumor is required. For reliable evaluation
of germline and somatic mutations in these genes in DNA
derived from formalin-fixed, paraffin-embedded (FFPE)
tissue, we have developed a single-molecule molecular in-
version probe (smMIP)-based targeted next-generation se-
quencing (NGS) approach. Our smMIP-based NGS ap-
proach provides analysis of both strands of the open
reading frame of BRCA1 and BRCA2, enabling the dis-
crimination between real variants and formalin-induced
artefacts. The single molecule tag enables compilation
of unique reads leading to a high analytical sensitivity
and enabling assessment of the reliability of mutation-
negative results. Multiplex ligation-dependent probe am-
plification (MLPA) and Methylation-specific multiplex
ligation-dependent probe amplification (MS-MLPA) were
used to detect exon deletions of BRCA1 and methylation
of the BRCA1 promoter, respectively. Here, we show that
this combined approach allows the rapid and reliable de-
tection of both germline and somatic aberrations affecting
BRCA1 and BRCA2 in DNA derived from FFPE OCs,
enabling improved hereditary cancer risk assessment and
clinical treatment of ovarian cancer patients.
Hum Mutat 38:226–235, 2017. Published 2016 Wiley Periodi-
cals, Inc.∗∗
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Introduction
Ovarian carcinoma (OC) is one of the most frequently diag-
nosed types of cancer in females in Europe with an age-standardized
incidence rate of 13.1 per 100,000 [Ferlay et al., 2013]. OC is
most frequently diagnosed in patients above the age of 65 years
[Yancik, 1993; Lowe et al., 2013]. However, the average age of on-
set is lower in patients who carry an OC predisposing germline
aberration [Prat et al., 2005; Weissman, et al., 2012]. During
the last decades, a modest improvement in OC survival has
been reported [Lowe et al., 2013], but due to the low mean
age-standardized 5-year survival (37.6%), the estimated number
of OC-related deaths remains high in Europe (7.6 per 100,000;
age-standardized rates) [Ferlay et al., 2013; De Angelis et al.,
2014].
A promising novel therapy for OC patients is based on the inhi-
bition of poly(ADP-ribose) polymerase (PARP), which is synthet-
ically lethal in cancer cells with acquired inactivation of the ho-
mologous recombination-mediated repair pathway [Bryant et al.,
2005; Farmer et al., 2005]. Multiple clinical trials with PARP in-
hibitors, including olaparib and niraparib, have demonstrated tol-
erability and efficacy of these treatments in OC patients [Audeh
et al., 2010; Sandhu et al., 2013]. Moreover, progression-free sur-
vival of OC patients is further improved when olaparib is admin-
istered in combination with other treatments (e.g., paclitaxel, car-
boplatin, and cediranib) [Liu et al., 2014; Oza et al., 2015]. Since
PARP inhibitors are predominantly lethal for cells that have lost
the ability of homologous recombination-mediated repair, patients
who have developed tumors with defects in this pathway show
the highest response rates to such treatment [Mateo et al., 2015].
The highest response rates to treatments with olaparib were ob-
served in OC patients with mutations affecting the homologous
recombination genes BRCA1 (MIM# 113705) or BRCA2 (MIM#
600185) [Audeh et al., 2010; Ledermann et al., 2014]. Since ge-
nomic aberrations affecting BRCA1 and BRCA2 are among the
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most prevalent mutations observed in OCs [Cancer Genome Atlas
Research, 2011; Kanchi et al., 2014; Patch et al., 2015], a substantial
number of OC patients may benefit from treatments with PARP
inhibitors.
Genomic aberrations affecting BRCA1 and BRCA2 are frequently
encountered in both sporadic and familial OCs [Cancer Genome
Atlas Research, 2011; Kanchi et al., 2014] (OMIM #604370 and
#612555). Approximately 10%–15% of all OC patients carry a
pathogenic germline aberration in BRCA1 or BRCA2 [Daly et al.,
2010; Hennessy et al., 2010; Kanchi et al., 2014]. Loss of het-
erozygosity (LOH) of the wild-type allele is the tumor-initiating
second hit in the majority of these patients [Foster et al., 1996;
Berchuck et al., 1998]. Somatic mutations in BRCA1 and BRCA2
are observed in approximately 3.5%–8.5% and 2.5%–4% of OCs
without an underlying germline mutation, respectively [Merajver
et al., 1995; Foster et al., 1996; Berchuck et al., 1998; Cancer
Genome Atlas Research, 2011; Kanchi et al., 2014]. Hypermethy-
lation of the promoter of BRCA1 is observed in approximately
10%–15% of these carcinomas [Baldwin et al., 2000; Bianco et al.,
2000; Esteller et al., 2000; Cancer Genome Atlas Research, 2011].
Importantly, germline mutations, somatic mutations, and pro-
moter hypermethylation appear mutually exclusive in OCs [Can-
cer Genome Atlas Research, 2011; Dworkin et al., 2009]. In total,
BRCA1 and BRCA2 are mutated in 19%–22% of OCs and, con-
sequently, these patients may benefit from PARP-inhibitor treat-
ment [Hennessy et al., 2010; Cancer Genome Atlas Research, 2011;
Kanchi et al., 2014]. Based on the genetic heterogeneity of the ob-
served mutation spectrum, sequencing of the entire open-reading
frame (ORF) of BRCA1 and BRCA2 using tumor-derived DNA
is required to identify the patients who may benefit from this
treatment.
Sequencing of BRCA1 and BRCA2 using tumor-derived DNA
is hampered by the complexity of these genes, the low quality of
the DNA derived from formalin-fixed, paraffin-embedded (FFPE)
tumor samples and the low percentage of neoplastic cells in these
samples. Several next-generation sequencing (NGS) approaches to
determine the mutation status of BRCA1 and BRCA2 have been
developed, but most approaches were validated using high-quality
DNA (i.e., blood-derived DNA) [Feliubadalo et al., 2013; Hirotsu
et al., 2015; Strom et al., 2015]. Therefore, these approaches can
successfully be implemented in a diagnostic setting to screen for
germline defects in BRCA1 and BRCA2 using blood-derived DNA
[D’Argenio et al., 2015; Trujillano et al., 2015], but cannot be used
to sequence low quality and highly fragmented DNA derived from
FFPE tumor blocks. Recently, three multiplex PCR-based targeted
NGSmethods to sequenceBRCA1 andBRCA2 inDNAderived from
FFPE material have been evaluated [Ellison, et al., 2015; Mafficini,
et al., 2016]. However, these methods have relatively low levels of
amplicon tiling, do not allow for strand-specific amplification, and
lack single molecule tagging. As a consequence, possible drop-outs
of amplicons andPCR jackpotting effectsmay result in false-negative
results [Ellison et al., 2015] or false-positive calls due to deamination
artefacts [Lou et al., 2013; Chen et al., 2014; Wong et al., 2014] and
detection of low frequency variants is hampered [Jabara et al., 2011;
Hiatt et al., 2013].
Here, we show that single-molecule molecular inversion probe
(smMIP)-based targeted sequencing [Hiatt et al., 2013] is a re-
liable method to detect both germline and somatic mutations
in BRCA1 and BRCA2 in FFPE samples, which can be applied
to identify OC patients who may benefit from treatments with




A retrospective cohort of OC patients who were tested for
germline BRCA1 and BRCA2 mutations after genetic counselling
at the department of Human Genetics of the Radboudumc or
the MaastrichtUMC+ was selected. All patients included signed in-
formed consent for the use of stored material for research purposes
(Radboudumc) or did not refuse use of stored material for research
purposes (according to local policy, MaastrichtUMC+). OC derived
from patients with a pathogenic germline BRCA1 or BRCA2muta-
tion were included in our study regardless of the histological phe-
notype. In contrast, of patients without a germline mutation only
those reported as serous OCwere selected. Histological revision was
performed for all tumors by an expert pathologist (MS and JB).
FFPE OCs were obtained between 1998 and 2014 at different time
points during treatment and were categorized as either diagnostic
(biopsy or primary debulking operation) or postchemotherapy (in-
terval or secondary debulking operation). This study was approved
by the medical ethics committee/institutional board (CMO, study
2014-1472) of the Radboudumc.
Isolation and Quality Assessment of FFPE Ovarian
Cancer-Derived DNA
DNA isolation fromFFPEOC samples was performed using stan-
dard procedures. First, 200 μl of 5% Chelex-100, diluted in TET
lyses buffer with GlycoBlue, and 20 μl proteinase K (20 mg/ml)
were added to the isolated sections of the FFPE ovarian cancer. This
sample was sequentially incubated andmixed (350 rpm) at 56°C for
16hr, at 37°C for 48hr, and 95°C for 10min. Incubationwas followed
by centrifugation at 16,000g for 1 min at room temperature and the
supernatant was collected. Next, 20μl of NaAc (3M, pH 5.2) and
440μl ice-cold ethanol (EtOH) was added to the supernatant (on
ice) and mixed. After centrifugation at 16,000g for 10 min at 4°C,
the supernatant was removed and the remaining pallet was washed
with 1 ml ice-cold 70% EtOH. To remove the EtOH, the sample was
centrifuged at 16,000g for 2 min at 4°C and the supernatant was
removed. The pellet was air-dried and, subsequently, dissolved in
80μl of TE and incubated for 5min at 56°C.TheDNAconcentration
was determined (Qubit Fluorometer; Life Technologies, Carlsbad,
CA) and amplifiability of the DNA was assessed by PCR-based am-
plification of DNA fragments of 115 and 216 bp (see Supp. Data).
Failed amplification of DNA fragments of 115 and 216 bp would
probably inhibit subsequent proper smMIP-based targeting of the
regions of interest sinceDNA fragments of 152bp are captured using
this approach.
Targeted Sequencing of BRCA1 and BRCA2 by smMIPs
A total of 157 and 260 smMIPs were designed, covering all cod-
ing regions and intron–exon boundaries of BRCA1 and BRCA2,
according to previously published methods [O’Roak et al., 2012;
Hiatt et al., 2013; Boyle et al., 2014] with minor modifications (see
Neveling et al., in press; and Supp. Table S1). Briefly, these 75–80 bp
long oligonucleotides (i.e., smMIPs; ordered from Integrated DNA
Technologies, Interleuvenlaan, Belgium) contained extension and
ligation arms (40-45bp) and a linker sequence (30bp) and were de-
signed to capture a target region of 112 nucleotides. In addition, all
smMIPs contained a stretch of five random nucleotides (molecu-
lar tag), enabling the detection of 1,024 unique (tagged) reads per
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smMIP. Both DNA strands (i.e., plus and minus strand) of the tar-
get regions were targeted by independent smMIPs, enabling double
tiling of these regions of interest. If the extension or ligation arm
targeted a common SNP (MAF > 1%), two different smMIPs were
designed to recognize and target both alleles. Next, smMIPs were
pooled in an equimolar manner and phosphorylated by adding
T4 polynucleotide kinase and 10x T4 DNA ligase buffer supplied
with 10mM ATP (New England Biolabs, Ipswich, MA). To improve
proper and equal coverage of the target regions, the smMIP pool
was rebalanced based on initial sequencing results obtained using
reference (blood-derived) DNA [Neveling et al., in press]. Targeted
sequencing of BRCA1 and BRCA2 using DNA derived from FFPE
OCs was performed as previously described [Weren et al., 2015],
using a slightly modified smMIP capture protocol [O’Roak et al.,
2012; Hiatt et al., 2013]. Briefly, smMIP capture was performed on
10μl of input DNA (20–500ng) supplied with 15μl capture mixture
(0.01μl ampligase DNA ligase [100U/μl; Illumina, Madison, WI],
2.5μl 10x ampligase buffer [Illumina], 0.27μl smMIP pool dilution
[6.6x105 μM], 0.32μl Hemo Klentaq [10U/μl; New England Bio-
labs], 0.03μl dNTPs [0.25mM], and 11.9μl H2O). The mixture was
incubated at 95°C for 10 min, and subsequently at 60°C for 24 hr.
Incubation was followed by exonuclease treatment: 0.5μl exonucle-
ase I (New England Biolabs), 0.5μl exonuclease III (New England
Biolabs), 0.2μl 10x ampligase buffer (Illumina), and 0.8μl H2O was
added to the (cooled) capture samples (consecutively incubated at
37°C and 95°C for 45 and 2 min, respectively). Subsequently, 10μl
of the samplewas used to perform aPCR reaction by adding 1.3μl of
barcoded reverse primer (10μM; Illumina), 12.5μl 2x iProof (Bio-
Rad Laboratories, Veenendaal, the Netherlands), 0.125μl forward
primer (100μM; Illumina), and 1.075μl H2O (final volume: 25μl;
PCR program: 98°C, 30 sec – 24x [98°C, 10 sec - 60°C, 30 sec - 72°C,
30 sec] - 72°C, 2min - 4°C,). Sequencing of the barcoded samples
was performedusing the IlluminaNextSeq500 system,with 2× 151-
bp paired-end reads; smMIP libraries required spike-in of custom
primers as described previously [O’Roak et al., 2012]. On average,
44 OC samples were sequenced per NextSeq500 Mid Output run.
Obtained bcl files were converted into fastq files that were separated
by barcode. Double tiling was achieved for up to 99.3% of the ORF
of BRCA1 and BRCA2, including the –20 and +20 intronic regions.
Fastq files were analyzed using the SeqNext software package (ver-
sion 4.2.2; JSI Medical Systems GmbH, Kippenheim, Germany).
Briefly, based on the single-molecule tag, consensus reads were gen-
erated and variants in coding regions were called if present in 5%
of all reads and 3 unique variant reads. For details, see Supple-
mentary Data.
Sequencing Data Analysis
Fastq files were analyzed using the SeqNext software package (ver-
sion 4.2.2; JSI Medical Systems GmbH, Kippenheim, Germany).
First, sequencing read data (fastq files) were mapped to exonic re-
gions plus adjacent intronic regions of BRCA1 (NM 007294.3) and
BRCA2 (NM 000059.3). Reads with undefined nucleotides in their
barcodes or of low quality were ignored, and to generate consensus
reads, all bases should be sequenced at least once in the consensus
reads, at least two tagged reads are required to create a consensus
read, and reads with less than 30% consensus were discarded. Reads
were excluded from alignment if these contain more than 15%mis-
matches compared with the reference or if less than 50%of the bases
match to the reference. Theminimal absolute sequencing depth and
expected sequencing depth for variant callingwere 20 and 30 unique
reads, respectively. In addition, variantswere called if the variantwas
observed in  5% of all reads and  3 unique variant reads were
present. To exclude (FFPE induced) cytosine deamination artefacts,
C:G>T:A transition calls were manually discarded if the variant was
notpresent in the smMIPcovering theopposite strand (i.e., targeting
the guanine nucleotide). Subsequently, all variants in coding regions
and the intron–exonboundaries ofBRCA1 andBRCA2were selected
for analysis. Variants were considered common SNPs if these were
observed in our in-house database of BRCA1 and BRCA2 germline
variants (accessed 01/03/2016; our in-house database contains 264
and 413 germline variants (in the close proximity) of theBRCA1 and
BRCA2 locus, respectively). We previously applied BRCA sequenc-
ing (i.e., exonic- and adjacent intronic regions) on blood-derived
DNA from 76 patients (of whom 90 of the 107 OCs were derived)
using Sanger- or Iontorrent-based sequencing prior to this study. All
germline variants inBRCA1 andBRCA2 that were identified in these
screenings were included in our analysis to confirm that these vari-
ants were also present in the smMIP-based targeted sequencing data
derived from the patient-matched FFPE samples. The other 17 pa-
tients had only been evaluated for the mutation segregating in their
family. Insertion and deletion calls in regions known to be prone for
false-positive calls (i.e., variant calls in homopolymer stretches of
eight adenine residues and variant calls in nucleotides at the end of
a sequencing read, which were not present in the sequencing reads
derived from overlapping smMIPs) were considered false positives.
Remaining variants were validated using Sanger sequencing or by
independent resequencing of the corresponding sample using our
smMIP-based targeted sequencing approach. Variants were submit-
ted to the locus-specific databases at LOVD: www.lovd.nl/BRCA1,
www.lovd.nl/BRCA2.
To determine the accuracy per nucleotide of our method, we de-
termined the number of true positives (n = 996), false positives (n
= 14), and false negatives (n = 18) based on the results of 107 sam-
ples. The number of true negatives (n = 1,442,122) was determined
based on 90 samples of which both BRCA genes were completely
sequenced using Sanger- or Iontorrent-based sequencing of blood-
derived DNA prior to the smMIP-based NGS analysis.
Multiplex Ligation-Dependent Probe Amplification
Methylation-Specific Multiplex Ligation-Dependent Probe
Amplification
Multiplex ligation-dependent probe amplification (MLPA) was
performed according to the manufacturers protocol to detect in-
tragenic copy-number variations affecting BRCA1 [kit P077; MRC
Holland, Amsterdam, The Netherlands]. For data analysis, the Gen-
eMarker software (Softgenetics, State College, PA) was used using
the population normalizationmode. Using this population normal-
ization mode, possible chromosomal aberrations at other genomic
regions (e.g., aneuploidies) would not hamper the MLPA analysis
(in contrast to other approaches that only use probes outside the
genomic locus of BRCA1 as a reference). In short, MLPA analysis
was performed with 38 probes targeting the BRCA1 locus and 10
probes targeting other chromosomes. For data analysis, peak inten-
sities were adjusted based on the average of peak intensities from all
probes (i.e., population normalization). Methylation-specific mul-
tiplex ligation-dependent probe amplification (MS-MLPA)was per-
formed and analyzed according to the manufacturers protocol (kit
ME001 C2) (MRC Holland).
LOH Analysis
LOH of the BRCA1 and the BRCA2 locus was determined using
the variant allele frequency (VAF) of common SNPs (n = 16 for
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BRCA1;n=20 forBRCA2) and confirmedgermline variants called in
a heterozygous state (5%VAF95%). As 95%of the samples had a
neoplastic cell percentage of at least 32% (median 65%, range 15%–
90%), an average major VAF of >60% was considered as a marker
for LOHof the corresponding locus. Noteworthy, LOH analysismay
have been hampered by the low percentage of neoplastic cells in a
minor subset of these samples.
Statistics
A two-tailed Fisher exact test was applied to determine whether
the frequency of high-grade serous OCs statistically differed be-
tween patients with a germline mutation in BRCA1 or BRCA2. The
predetermined level of significance was P = 0.05.
Results
Sample Selection and Coverage of smMIP-Based
Sequencing of BRCA1 and BRCA2
For the evaluation of our approach, 127 ovarian tumor samples
derived from 96 patients were tested: 29 with a BRCA1, 14 with a
BRCA2, and 53 without a germline mutation in either gene. For 20
samples, including 16 samples that were poorly amplifiable based
on our control PCRs, the sequencing depth of the ORF of BRCA1
and BRCA2 and total number of mapped reads was low (Supp. Fig.
S1A and B). In the remaining 107 samples, the average number
of unique reads per smMIP (after deconvolution of the PCR du-
plicates) was high (Fig. 1A). The average number of unique reads
per coding base pair (including canonical splice sites) was 647 for
BRCA1 (146–1,476) and 592 forBRCA2 (47–1,679) (Supp. Fig. S1C)
(for the total number of tagged reads, see Supp. Fig. S1D). These
unique reads were equally mapped to the plus and minus strands of
the ORF, revealing that both strands were successfully targeted by
ourmethod (Fig. 1B). On average, 98.8% and 97.4%of theORFs in-
cluding the –20 and +20 intronic regions ofBRCA1 and BRCA2were
covered with at least 20 and 30 unique reads reflecting a 95% chance
of detecting a variant with a VAF of 30% and 20%, respectively
(Fig. 1C).
Interpretation of smMIP-Based Mutation Detection
All pathogenic germlinemutations inBRCA1 (n = 31) andBRCA2
(n = 16), known prior to smMIP-based targeted sequencing, were
called by the NextSeq software in 47 tumor samples derived from 38
patients (Fig. 2A). The average number of unique variant reads and
percentage of variant calls was high for these variants in bothBRCA1
(524 [28–2,125]; 82.3% [64%–95%]) and BRCA2 (686 [23–2,832;,
71.3% [45%–94%]) (Table 1). Moreover, 745 out of 763 class 1/2
germline variants, known prior to smMIP-based targeted sequenc-
ing in 90 samples, were called (Fig. 2B). Based on the detection of
792/810 germline variants, an overall sensitivity of 97.8% (95% CI,
96.8%–98.8%) is estimated. The positions of the 18 variants that
were not called using our standard variant calling settings were in-
spected visually. Five variants were missed due to LOH leading to a
low percentage of variant reads in samples with a high tumor cell
percentage. Thirteen variants were false negative due to a poor read
depth at four SNP positions in five samples with a low number of
total mapped reads (< 20,000 unique reads) (Supp. Fig. S1E).
1,135 variants were called in 107 samples. In addition to the 47
pathogenic germline mutations, 937 of these variants were known
benign germline variants (class 1 or 2) present in our in-house
database of BRCA1 and BRCA2 variants. Of the remaining 151
variants, 125 were C:G to T:A transitions reflecting FFPE-induced
cytosine deamination artefacts (Supp. Table S2). The majority of
these (n = 64) were observed in only two samples. In total, 12
variants were somatic mutations as they were confirmed present
in the tumor, but absent in germline DNA. Five different somatic
mutations, represented in eight carcinomas from five patients, were
consideredpathogenic,whereas the other four somatic variantswere
considered benign passengermutations (Table 2). The remaining 14
variants were false-positive variant calls due to sequencing artefacts.
They were called with a low percentage and number of variant reads
(Supp. Fig. S2A and B) at either the last nucleotide of the targeted
region or in a stretch of eight adenosines. Thus, after exclusion of
deamination artefacts, the percentage of false-positive calls is low
(1.4%, 14/1,010).
In total, 16,033 nucleotides were analyzed per sample. Therefore,
based on these results, the accuracy per nucleotide of our method is
99.998%(996 truepositive, 14 false positive, 1,442,122 truenegative,
and 18 false negative).
Detection of Copy-Number Variants Affecting BRCA1
All 127 DNA samples were screened for copy-number variants
(CNVs) affecting the genomic locus of BRCA1 using MLPA. Prior
to this screening, it was established that three of these patients
carried a germline deletion encompassing exon 22 of BRCA1. These
deletions were confirmed in all FFPE OC samples (n = 4) derived
from these patients. No CNVs were detected in the other FFPE OC
samples. Noteworthy, the relative number of unique reads covering
exon 22 was strongly decreased in the smMIP NGS data derived
from patients with a germline deletion affecting this exon (Supp.
Fig. S3).
Detection of BRCA1 Promoter Methylation
Possible methylation of the BRCA1 promoter was determined us-
ing a MS-MLPA assay for all 127 DNA samples. Methylation of the
promoter of BRCA1 was not observed in FFPE OC samples derived
from patients with a germline or somatic pathogenic mutation af-
fecting BRCA1 (n = 43) or BRCA2 (n = 22). In contrast, methylation
of the BRCA1 promoter was observed in 13 samples derived from
17% of the sporadic patients (9/53). In all 24 patients, from whom
multipleOC specimenwere available, themethylation of theBRCA1
promoter was fully concordant in tumor samples at diagnosis and
at interval or secondary debulking (Supp. Table S3).
LOH
LOH was based on the allele frequency of BRCA1 and BRCA2
mutations and germline variants (n = 31 for BRCA1; n = 49 for
BRCA2) that were called in a heterozygous state (5% VAF 95%)
(Supp. Fig. S4). Informative SNPs in BRCA1 and BRCA2 were ob-
served in 100 and 103 samples, respectively (Supp. Table S4). In
concordance with BRCA1 germline mutant allele frequencies of >
60% that suggest loss of the wild-type allele (Table 1), all FFPE
samples derived from patients with a pathogenic germline muta-
tion in BRCA1 revealed LOH of the BRCA1 locus. Similarly, LOH
is presumed in the tumor samples from the two sporadic patients
with a somatic pathogenic BRCA1mutation and in all samples with
BRCA1 promoter methylation (Supp. Table S5).
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Figure 1. A: Average number of unique reads per smMIP. X-axis: number of unique smMIPs included in our panel to sequence BRCA1 (n =
157 smMIPs) and BRCA2 (n = 260 smMIPs) (ordered for the genomic position of the target). Y-axis: number of unique reads obtained per smMIP.
The average and median number of unique reads per smMIP is 254 and 154, respectively. Numbers are based on sequencing results obtained
from 107 FFPE samples (for details; see main text or Materials and Methods). B: Number of unique reads/smMIPs mapping to/targeting the plus
or minus strand of the ORF of BRCA1 and BRCA2. smMIPs targeting plus/minus strand: total number of smMIPs targeting the plus/minus strand of
the corresponding base-pair position (range 0–3 smMIPs per strand per position). Average reads plus/minus strand: average number of unique
reads mapping to the plus and minus strand based on 107 ovarian carcinoma samples. On average, the plus/minus strand were covered 356x/291x
(BRCA1) and 334x/258x (BRCA2), respectively. Bars on the X-axis represent the nucleotides located in the exons of BRCA1 and BRCA2, including
the canonical splice sites. Red bars indicate regions (4 and 16 bp, respectively) without any smMIPs or mapped reads at the corresponding locus.
Note that 100% of the ORF including the canonical splice sites is sequenced and that 99.8% is sequenced on both the plus and minus strand. C:
Percentage of the ORF of BRCA1 and BRCA2 covered with at least 20 and 30 unique reads in 107 FFPE ovarian carcinoma samples. On average,
98.8% (median 99.8%, range 79.3%–100%) and 97.4% (median 99.6, range 60.9%–100%) of the ORF of BRCA1 and BRCA2, including the −20 and +20
intronic regions, was covered with a sequencing depth of at least 20x and 30x, respectively.
LOH at the BRCA2 locus was observed in 73% of the FFPE sam-
ples derived from carriers of a pathogenic germline mutation in
BRCA2 (Supp. Table S4). Based on these data, we consider that
LOH occurred in the OC of 12 out of 14 patients (86%) with a
BRCA2 germline mutation (Table 1). LOH of the wild-type allele
is presumed in all four lesions with a somatic pathogenic BRCA2
mutation (Table 2; Supp. Table S5).
LOH of the respective loci is not an indication for a BRCA1
or BRCA2 mutation. LOH at the BRCA1 locus was observed in
73% of the tumors with a pathogenic germline mutation in BRCA2
and in 80% of the tumors without a somatic pathogenic mutation
in BRCA1 or methylation of the BRCA1 promoter. LOH of the
BRCA2 locus was observed in 56% of tumors with a pathogenic
germline mutation in BRCA1 and in 46% of the sporadic tumors
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Figure 2. A: Pathogenic germline and somatic mutations in BRCA1 and BRCA2 detected using smMIP-based targeted sequencing of FFPE tumor
material. Lollipops above the bar: germline mutations detected in 47 FFPE ovarian carcinomas derived from 38 patients. Lollipops below the bar:
somatic pathogenic mutations observed in seven FFPE ovarian carcinomas derived from five patients. B: Genomic location of 43 germline SNPs
in BRCA1 and BRCA2 that were selected to determine the sensitivity of smMIP-based next-generation sequencing. Depicted base substitutions
(lollipops) represent 15 and 28 benign germline variants in the ORF of BRCA1 and BRCA2, respectively. These variants were known to be present in
the germline of a subset of the included ovarian carcinoma patients prior to smMIP-based sequencing of BRCA1 and BRCA2 in the corresponding
FFPE ovarian carcinomas. Numbers depict the total number of the corresponding germline variant observed in these ovarian carcinoma patients.
All germline SNPs could successfully be detected using smMIP-based targeted sequencing on DNA derived from the corresponding FFPE ovarian
carcinoma sample.
without a somatic pathogenic mutation in BRCA2 (Supp. Tables S4
and S5).
Histology Review of the OCs
Histology revision by an expert pathologist revealed that 83% of
the carcinomas derived from germlinemutation carriers had a high-
grade serous histology (n = 35). The other patients with a germline
mutation in BRCA1 or BRCA2 presented carcinomas with a mixed
(n = 2), high-grade endometrioid (n = 1), clear cell (n = 1), and
poorly/undifferentiated (n = 3) histology (Supp. Table S6A). The
frequency of high-grade serous OCs did not differ between carci-
nomas derived from patients with a germline mutation in BRCA1
(22/28) or BRCA2 (13/14) (P = 0.39).
Although OCs of patients without a germline BRCA1 or BRCA2
mutation were selected based on their reported serous histology,
revision revealed that 13% of these patients did not develop low-
or high-grade serous carcinomas (seven out of 54). These patients
developed carcinomaswith amixed (n= 1), low-grade endometrioid
(n = 1), high-grade endometrioid (n = 1), or poorly/undifferentiated
(n = 4) carcinomas (Supp. Table S6B). All carcinomas that showed
methylation of the promoter of BRCA1 had a high-grade serous
histology (n = 9 patients). In contrast, high-grade serous histology
was observed in only three of the five carcinomas with somatic
pathogenic mutations in BRCA1 or BRCA2. Two patients with a
somatic pathogenic mutation in BRCA2 developed a carcinoma
with either a mixed or poorly/undifferentiated histology (Table 2).
Discussion
Reliable and sensitive analysis of the mutation status of BRCA1
andBRCA2 inFFPEOCsamples is important, nowthatpatientswith
germline and somatic pathogenic mutations in BRCA1 and BRCA2
are eligible for therapy with PARP inhibitors. Analysis of tumor
DNA can be used as a prescreen for germline mutation analysis in
blood only if germline mutations in tumor DNA can be assessed
efficiently. Here, we show that reliable analysis of germline and
somatic mutations is possible using a combination of smMIP-based
mutation detection and MLPA on DNA isolated from FFPE OCs.
Due to the high a priori risk of 10%–15% to carry a germline
BRCA1 or BRCA2 mutation, all new OC patients are now eligible
for germline DNA testing inmany countries, including The Nether-
lands [Lancaster et al., 2015; Oncoline, 2015]. Our novel method
enables reliable assessment of the tumor DNA mutation status of
BRCA1 andBRCA2 in FFPEmaterial derived fromOCs. Performing
such a BRCA tumor test on all newly diagnosed OC patients may
be an efficient way to select all patients who may eventually ben-
efit from treatment with PARP inhibitors and are simultaneously
at high risk of carrying a pathogenic germline BRCA mutation, as
approximately 75% of those that are tested positive for BRCA mu-
tations in the tumor will have a germline mutation (i.e., hereditary
predisposition; germline status of the mutation is confirmed in
DNA derived from blood) [Cancer Genome Atlas Research, 2011].
This would limit genetic counselling procedures and concomitant
distress to OC patients with a positive BRCA tumor test or a posi-
tive family history of ovarian cancer. This procedure would also be
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Table 1. Variant Calling of Germline Mutations in BRCA1 and BRCA2 in FFPE Samples
Patient ID Germline mutation Nucl. change AA change Carcinoma phenotype #FFPE samples Neoplastic cells (%) #Var. reads Var. reads (%) LOH
P040 BRCA1 c.3748G>T p.Glu1250∗ High-grade serous 3 70 127 64 Y
30 352 75 Y
80 709 80 Y
P016 BRCA1 c.5266dup p.Gln1756fs High-grade serous 2 70 77 80 Y
60 756 80 Y
P038 BRCA1 c.4964C> T p.Ser1655Phe High-grade serous 2 60–70 58 87 Y
70 97 74 Y
P057 BRCA1 c.5137delG p.Val1713fs High-grade serous 2 40 993 68 Y
90 1,120 82 Y
P070 BRCA1 c.3748G>T p.Glu1250∗ High-grade serous 2 65 102 79 Y
50–60 411 76 Y
P078 BRCA1 c.5266dup p.Gln1756fs Clear cell 2 40 2,125 79 Y
65 215 79 Y
P001 BRCA1 c.3748G>T p.Glu1250∗ Poorly/undifferentiated 1 50 58 87 Y
P007 BRCA1 c.2685 2686del p.Pro897fs High-grade serous 1 90 57 95 Y
P022 BRCA1 c.5485dup p.Glu1829fs High-grade serous 1 90 405 90 Y
P025 BRCA1 c.2019del p.Glu673fs High-grade serous 1 90 28 93 Ya
P029 BRCA1 c.68 69del p.Glu23fs High-grade serous 1 85 150 83 Y
P035 BRCA1 c.2722 G>T p.Glu908∗ High-grade serous 1 75 358 88 Y
P036 BRCA1 c.2197 2201del p.Glu733fs High-grade serous 1 80 483 89 Y
P039 BRCA1 c.5095C>T p.Arg1669Trp High-grade serous 1 70 322 84 Y
P046 BRCA1 c.2338C>T p.Gln780∗ High-grade serous 1 90 1,100 91 Y
P048 BRCA1 c.815 824dup p.Thr276fs High-grade serous 1 60–70 150 68 Y
P066 BRCA1 c.2269delG p.Val757fs High-grade serous 1 80–90 667 88 Y
P076 BRCA1 c.2685 2686del p.Pro897fs Mixed carcinoma 1 65 1,602 88 Y
P077 BRCA1 c.4057G> T p.Glu1351∗ High-grade serous 1 80 751 92 Y
P079 BRCA1 c.2019del p.Glu673fs Poorly/undifferentiated 1 90 190 86 Y
P085 BRCA1 c.2197 2201del p.Glu733fs Mixed carcinoma 1 70 1,134 90 Y
P093 BRCA1 c.5095C>T p.Arg1699Trp High-grade serous 1 65 265 80 Y
P094 BRCA1 c.2685 2686del p.Pro897fs High-grade serous 1 85 590 88 Y
P096 BRCA1 c.5503C>T p.Arg1835∗ High-grade endometrioid 1 60 786 68 Y
P028 BRCA2 c.4449del p.Asp1484fs High-grade serous 2 40 23 52 Y
30 282 63 Y
P086 BRCA2 c.3639 3652del p.Val1214fs High-grade serous 2 35 172 64 Pb
10–50 524 56 Pb
P006 BRCA2 c.4533del p.Glu1511fs High-grade serous 1 65 90 85 Y
P021 BRCA2 c.3599 3600del p.Cys1200∗ High-grade serous 1 50 138 55 Y
P034 BRCA2 c.2830A>T p.Lys944∗ High-grade serous 1 70 727 92 Y
P044 BRCA2 c.516+1G>T p.? High-grade serous 1 70 409 52 N
P067 BRCA2 c.582G>A p.Trp194∗ High-grade serous 1 45 2,832 84 Y
P068 BRCA2 c.5645C> G p.Ser1882∗ High-grade serous 1 60 89 79 Y
P069 BRCA2 c. 469 470del p.Lys157fs High-grade serous 1 40 515 45 N
P071 BRCA2 c.5213 5216del p.Thr1738fs High-grade serous 1 80 1,351 89 Y
P072 BRCA2 c.5213 5216del p.Thr1738fs High-grade serous 1 55 1,299 90 Ya
P073 BRCA2 c.7480C> T p.Arg2494∗ High-grade serous 1 50–90 81 66 Y
P074 BRCA2 c.7806-1G>T p.? High-grade serous 1 55 1,207 75 Y
P075 BRCA2 c.5213 5216del p.Thr1738fs Poorly/undifferentiated 1 90 1,232 94 Y
The indicated nucleotide change is based on the cDNA sequence.
aBased on pathogenic germline variant call in FFPE material; no additional informative SNPs available.
bPossibly LOH, but the analysis is hampered by the low percentage of tumor cells in the corresponding FFPE sample.
cost-effective as it will reduce the number of germline tests and de-
creases double testing on both tumor and germline DNA. We are
currently evaluating whether this altered diagnostic pathway start-
ing with tumor DNA BRCA testing in newly diagnosed ovarian
cancer as a prescreen for treatment and genetic counselling to initi-
ate germlineDNA testing onDNAderived fromblood is feasible and
is adopted as well as appreciated by both patients and professionals.
MostNGSapproaches todetermine themutation status ofBRCA1
and BRCA2 have been developed to sequence blood-derived, high-
quality DNA and, consequently, can only be implemented in a rou-
tine diagnostic setting to screen for germline mutations in these
genes [Feliubadalo et al., 2013; D’Argenio et al., 2015; Hirotsu et al.,
2015; Strom et al., 2015; Trujillano et al., 2015]. Our smMIP-based
NGS approach provides double tiling of the ORF of BRCA1 and
BRCA2 by targeting the plus and minus strand using independent
overlapping smMIPs and enables the detection of unique reads by
the introduction of a single-molecule tag. The detection of unique
reads enables the recognition of biased amplification of only a lim-
ited number of template molecules, which is commonly observed
when a low amount of amplifiable inputDNA is available (e.g., DNA
derived from FFPE OCs). Formalin-induced cytosine deamination
artefacts, which frequently occur in DNA derived from FFPE sam-
ples [Chen et al., 2014], can be recognized due to the targeting of
the plus and minus strand using independent overlapping smMIPs
(i.e., double tiling). Our approach enables the reliable detection of
mutations in BRCA1 and BRCA2 in DNA derived from FFPE mate-
rial. Furthermore, since smMIP-based NGS is a low-cost and easily
scalable method, extending this approach to sequence additional
genes in FFPE samples is feasible [O’Roak et al., 2012; Kumar et al.,
2014]. Since patients with defects in other homologous recombi-
nation genes may also benefit from PARP inhibitors, extending our
smMIPdesignwith probes targeting these genes could be considered
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Table 2. Variant Calling of Somatic Mutations in BRCA1 and BRCA2 in FFPE Samples
Patient ID Gene Nucleotide change Amino acid change Carcinoma phenotype #FFPE samples Neoplastic cells (%) #Var. reads Var. reads (%) Pathogenica LOH
P047 BRCA1 c.121del p.His41fs High-grade serous 2 60–70 486 41 Yes Yes
35 53 16 Pb
P061 BRCA1 c.929del p.Gln310fs High-grade serous 2 60 18 24 Yes Yes
50 19 23 Yes
P050 BRCA2 c.7971dup p.Tyr2658fs Mixed carcinoma 2 50 689 52 Yes V
Yes 634 66 Yes
P062 BRCA2 c.51 52del p.Arg18Leufs Poorly/undifferentiated 1 90 789 75 Yes Yes
P091 BRCA2 c.7878G>C p.Trp2626Cys High-grade serous 1 70 339 47 Yes Yes
P048c BRCA2 c.6970C>G p.His2324Asp High-grade serous 1 60–70 235 37 Nod No
P063 BRCA2 c.4154C>T p.Ser1385Leu Low-grade endometrioid 1 30 55 8 Noe Yes
P063 BRCA2 c.4347C>G p.Phe1449Leu Low-grade endometrioid 1 30 128 6 Nof Yes
P079c BRCA2 c.8599A>C p.Thr2867Pro Poorly/undifferentiated 1 90 59 36 Nog No
The indicated nucleotide change is based on the cDNA sequence.
aVariants were considered pathogenic as they were either truncating or a known class 5 missense mutation and considered benign passenger mutations based in in silico prediction
tools.
bProbably LOH, but the analysis is hampered by the low percentage of tumor cells in the corresponding FFPE sample.
cPatients with a BRCA1 germline mutation.
dWeakly conserved nucleotide (PhyloP: 1.90), Align GVGD: class C0 (GV: 130.59; GD: 22.66), SIFT: tolerated (score: 0.39).
eWeakly conserved nucleotide (PhyloP: 1.58), Align GVGD: class C0 (GV: 353.86 - GD: 0.00), SIFT: tolerated (score: 0.51).
fWeakly conserved nucleotide (PhyloP: 0.29), Align GVGD: class C0 (GV: 180.03 - GD: 0.00), SIFT: tolerated (score: 1).
gWeakly conserved nucleotide (PhyloP: 0.61), Align GVGD: class C0 (GV: 129.31 - GD: 1.62), SIFT: tolerated (score: 0.07).
For more details regarding these in silico predictions, see Supplementary Data.
[McCabe et al., 2006;Mateo et al., 2015]. This smMIP-based analysis
of BRCA1 and BRCA2 is a paradigm for reliable mutation analysis
of complete ORFs or hotspot regions of other genes [Eijkelenboom
et al., 2016].
If settings are used that filter out deamination artefacts, the
amount of false-positive calls using standard variant calling set-
tings at a cut-off value of 5% VAF is very low. In our analysis, no
false-positive calls were observed in 90% of the samples (96/107),
whereas in nine samples only a single false-positive variant was
called and in two samples two and three false-positive variants were
called, respectively. All these calls could easily be recognized as false-
positive calls. Therefore, interpretation of sequencing results is very
objective. The sensitivity of our smMIP-based NGS approach was
97.8% based on standard variant calling of 810 BRCA1 and BRCA2
germline variants (100% was detected by visual inspection). Vari-
ants were missed either due to insufficient sequencing depth at
three specific regions in samples with relatively low total coverage
or due to loss of the allele containing the SNP, a phenomenon often
observed in human cancers [Lengauer et al., 1998]. If germline mu-
tations in BRCA1 or BRCA2 underlie the development of an OC,
LOH will generally affect the allele without the causative germline
mutation leading to an increase inmutant allele frequencies [Cancer
Genome Atlas Research, 2011; Kanchi et al., 2014]. However, low
frequent variant calls can reliably be detected using smMIP-based
NGS; we successfully identified somatic (passenger) variants with
a low percentage of variant reads (e.g., 6% VAF). Noteworthy, the
detection of low-percentage variant calls can be easily improved by
increasing the length of the molecular tag; a stretch of eight ran-
dom nucleotides would enable the detection of 65,536, instead of
1,024, unique reads per smMIP [Hiatt et al., 2013]. Nevertheless,
caution is required regarding the detection of germline variants in
cancer samples with a high percentage of neoplastic cells (>90%),
especially if mutation analysis is performed on tumor samples that
are obtained after chemotherapy, as therapymay lead to reversion of
the mutation [Norquist et al., 2011; Patch et al., 2015]. We have not
yet optimized the detection of exon deletions and duplications that
may inactivate BRCA1 and BRCA2 using our smMIP approach. For
these aberrations, MLPAmethods that are currently used in routine
diagnostics of germline mutations can be applied.
Infiveof the51ovarian cancerpatientswithout a germlineBRCA1
or BRCA2 mutation included in this study, a somatic, pathogenic
mutation affecting BRCA1 or BRCA2 was encountered. This con-
firms that these somatic mutations are relatively common in spo-
radic ovarian cancer patients [Cancer GenomeAtlas Research, 2011;
Kanchi et al., 2014]. In comparison with amplicon-based target en-
richment, our smMIP-based approach has the advantage that the
number of sequenced template molecules can be measured using
the single-molecule tag. This allows a proper risk estimation of the
probability of false-negative results given a chosen limit of detection
[Eijkelenboom et al., 2016]. Our analyses were aimed at a minimal
sequencing depth of 30 unique reads, which should be sufficient
to detect >95% of variants present at a VAF of 20% or higher. On
average, 97.4% of the ORF including 20 exon-flanking nucleotides
of BRCA1 and BRCA2 reached this sequencing depth, which was
mostly much higher reflecting high complexity of our sequence li-
braries. Given the percentages of neoplastic cells in our samples was
at least 40% in 90% of the tumor samples derived from sporadic
patients, the chance that a somatic mutation was missed is low.
Acquired hypermethylation of the promoter of BRCA1 in the
OC was observed in 17% of the patients without a germline BRCA
mutation. As described by others [Cancer Genome Atlas Research,
2011], hypermethylation was mutually exclusive with germline and
somaticBRCA1 andBRCA2mutations. In linewith previous reports
[Esteller et al., 2000], we noticed that LOH of BRCA1 was observed
in all OCs withmethylation of the BRCA1 promoter, suggesting that
the hypermethylation is driving the tumourigenesis and will proba-
bly lead to homologous recombination-deficient tumors. Therefore,
patients who develop OCs with hypermethylation of the BRCA1
promoter are predicted to benefit from PARP-inhibitor treatments
[Stefansson et al., 2012; Veeck et al., 2010]. A systematic evaluation
of the effect of PARP inhibitors in this patient group seems justified.
It has been reported that the BRCA1 or BRCA2 gene is affected by
a germline mutation, somatic mutation, or epigenetic silencing in
approximately 33% of the high-grade serous OCs [Cancer Genome
Atlas Research, 2011]. Genomic aberrations affecting BRCA1 and
BRCA2 are most common in high-grade serous OCs, although they
also occur in other subtypes [Hennessy et al., 2010; Alsop et al.,
2012]. Our results support that the majority of the carriers of
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germline mutations in BRCA1 and BRCA2 develop (high-grade)
serous OCs [Boyd et al., 2000; Hennessy et al., 2010]; however, a sig-
nificant subset (17%) of OCs derived from patients with germline
mutations in BRCA1 and BRCA2 reveal a different histological phe-
notype. Therefore, we recommend that sequencing of BRCA1 and
BRCA2 should be considered in all patients with OCs irrespective
of their histological subtype.
In conclusion, a combined approach of smMIP-based NGS,
MLPA, andMS-MLPA allows the reliable detection of both germline
and somatic alterations affecting BRCA1 and BRCA2 in FFPE OCs
(MLPA and MS-MLPA were only performed for BRCA1). This ap-
proach enables the identification of (1) patients who may benefit
from therapeutic treatments that are based on the mutation status
of BRCA1 and BRCA2 (e.g., PARP-inhibitors) and (2) those at high
risk of a pathogenic germline mutation in BRCA1 and BRCA2 (i.e.,
hereditary predisposition). Therefore, our approach will further
improve clinical treatment and hereditary cancer risk assessment of
ovarian cancer patients.
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